natgillin/translations-raw huggingface dataset:
The difference between LIFMIOR alone and methotrexate alone was also significant (p<0.05). 
Pomembna je bila tudi razlika med monoterapijo z zdravilom LIFMIOR in monoterapijo z metotreksatom (p < 0,05).
Inspect the solution in the pen by looking through the clear inspection window. 
Preglejte raztopino v peresniku, tako da pogledate skozi prozorno okence za pregledovanje.
Serious infections affect fewer than 1 in 100 patients treated with LIFMIOR. 
Med zdravljenjem z zdravilom LIFMIOR so se resne okužbe pojavile pri manj kot 1 od 100 bolnikov.
Patients who “failed to respond to” in the target population is defined by insufficient response (PASI<50 or PGA less than good), or worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long duration to assess response with at least each of the three major systemic therapies as available. 
Bolnike v ciljni populaciji, ki ''se niso odzvali'', opredeljuje nezadosten odziv (PASI  50 ali PGA [PGAPhysician Global Assessment] manj kot dober) ali poslabšanje bolezni med zdravljenjem, ko je bolnik prejemal najmanj vsako od treh glavnih razpoložljivih sistemskih zdravljenj v zadostnem odmerku in dovolj časa, da je bilo mogoče oceniti odziv.
In each of the JIA subtypes, the majority of patients met ACR Pedi 30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender joints and physician global assessment. 
Pri vseh podtipih JIA so bili kriteriji ACR Pedi 30 doseženi pri večini bolnikov, prav tako pa so pri večini bolnikov ugotovili tudi klinično izboljšanje pri sekundarnih opazovanih dogodkih, kot sta število občutljivih sklepov in zdravnikova splošna ocena.
It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating LIFMIOR therapy (see Vaccinations, above). 
Za pediatrične bolnike priporočamo, da pred začetkom zdravljenja z zdravilom LIFMIOR, če je le mogoče, opravijo vsa cepljenja v skladu z veljavnimi smernicami za cepljenje (glejte Cepljenja zgoraj).
Serum concentration profiles were similar to those seen in adult rheumatoid arthritis patients. 
Profili serumskih koncentracij so bili podobni tistim pri odraslih bolnikih z revmatoidnim artritisom.
LIFMIOR is prescribed for the treatment of the following diseases in children and adolescents 
Zdravilo LIFMIOR se predpisuje za zdravljenje naslednjih bolezni pri otrocih in mladostnikih:
Paediatric plaque psoriasis (age 6 years and above) 
Otroška psoriaza v plakih (starost 6 let in več)
Do NOT shake the vial. 
NE stresajte viale.
Use in children and adolescents 
Uporaba pri otrocih in mladostnikih
Other medicines and LIFMIOR 
Druga zdravila in zdravilo LIFMIOR
If active tuberculosis is diagnosed, LIFMIOR therapy must not be initiated. 
Če je postavljena diagnoza aktivne tuberkuloze, se zdravljenja z zdravilom LIFMIOR ne sme uvesti.
During the withdrawal period, symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. 
Med odtegnitvenim obdobjem so se simptomi psoriaze postopoma znova pojavili; mediani čas do recidiva bolezni je bil 3 mesece.
Wegener's granulomatosis 
Wegenerjeva granulomatoza
No data are available on the secondary transmission of infection by live vaccines in patients receiving LIFMIOR. 
Podatkov o sekundarnem prenosu okužbe z živimi cepivi pri bolnikih, ki prejemajo zdravilo LIFMIOR, ni na voljo.
Your doctor or nurse will tell you how to inject LIFMIOR. 
Zdravnik ali medicinska sestra vas bosta natančno poučila, kako si injicirate zdravilo LIFMIOR.
In a group of 2,711 plaque psoriasis patients treated with LIFMIOR in double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin cancers were reported. 
V skupini 2.711 bolnikov s psoriazo v plakih, zdravljenih z zdravilom LIFMIOR v dvojno slepih in odprtih študijah, ki so trajale do 2,5 leta, so poročali o 30 malignomih in 43 primerih nemelanomskega kožnega raka.
The study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs). 
V študijo je bilo vključenih 234 odraslih bolnikov z aktivnim revmatoidnim artritisom, ki so bili pred tem neuspešno zdravljeni vsaj z enim, a ne več kot 4 imunomodulirajočimi antirevmatičnimi zdravili (DMARD - Disease-Modifying AntiRheumatic Drug).
Treatment with LIFMIOR should not be initiated in patients with active infections, including chronic or localised infections. 
Zdravljenja z zdravilom LIFMIOR ne smete uvesti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi okužbami.
• Instructional materials to share with patients 
• gradivo z navodili za bolnike
Consequently, LIFMIOR should not be used in patients for the treatment of alcoholic hepatitis. 
Zato zdravila LIFMIOR ne smemo uporabljati pri bolnikih za zdravljenje alkoholnega hepatitisa.
If LIFMIOR has no effect on the child's condition after 12 weeks, your doctor may tell you to stop using this medicine. 
Če zdravilo LIFMIOR po 12 tednih nima nobenega učinka na otrokovo stanje, vam bo zdravnik morda naročil, da prenehajte uporabljati to zdravilo.
A different site should be used for each new injection. 
Za vsako naslednjo injekcijo morate uporabiti drugo mesto.
While neutropenic, one patient developed cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5). 
Med nevtropenijo se je pri enem bolniku pojavil celulitis, ki je po hospitalizaciji izzvenel (glejte poglavji 4.4 in 4.5).
LIFMIOR (n = 223) 
zdravilo LIFMIOR (n = 223)
Although no clinical trials have been performed evaluating LIFMIOR therapy in patients with multiple sclerosis, clinical trials of other TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. 
Čeprav niso opravili kliničnih preskušanj za ovrednotenje zdravljenja z zdravilom LIFMIOR pri bolnikih z multiplo sklerozo, so klinična preskušanja drugih antagonistov TNF pri teh bolnikih pokazala zvečano aktivnost bolezni.
In a pooled data set of clinical trials, the overall incidence of opportunistic infections was 0.09% for the 15,402 subjects who received LIFMIOR. 
V združeni zbirki podatkov iz kliničnih preskušanj je bila celokupna pojavnost oportunističnih okužb pri 15.402 bolnikih, ki so prejeli LIFMIOR, 0,09 %.
• For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not worked well enough or is not suitable for them: 
• za zdravljenje naslednjih tipov juvenilnega idiopatskega artritisa, če zdravljenje z metotreksatom ni bilo uspešno ali ga bolniki niso prenašali:
Clinical improvement, including onset of action within 2 weeks with LIFMIOR 25 mg, was similar to that seen in the previous trials and was maintained for up to 24 months. 
Klinično izboljšanje, vključno z nastopom delovanja zdravila v 2 tednih pri 25 mg zdravila LIFMIOR, je bilo podobno tistemu, ki so ga ugotavljali v prejšnjih preskušanjih, in se je ohranjalo do 24 mesecev.
Method of administration LIFMIOR is administered by subcutaneous injection (see section 6.6). 
Način uporabe Zdravilo LIFMIOR se daje s subkutano injekcijo (glejte poglavje 6.6).
Skin cancers 
Kožni rak
The doctor will provide you with detailed directions for preparing and measuring the appropriate dose. 
Otrokov zdravnik vam bo natančno pojasnil, kako pripraviti in odmeriti primeren odmerek.
• if you or the child have an infection of any kind. 
če imate vi ali otrok kakršnokoli okužbo.
You should consult your doctor if you become pregnant, think you may be pregnant, or are planning to have a baby. 
Če zanosite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom.
If LIFMIOR has no effect on your condition after 12 weeks, your doctor may tell you to stop taking this medicine. 
Če zdravilo LIFMIOR po 12 tednih nima nobenega učinka na vašo bolezen, vam zdravnik lahko naroči, da to zdravilo nehate uporabljati.
Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving Endpoints 
Odziv glede učinkovitosti v s placebom nadzorovani študiji nr-AxSpa: Odstotek bolnikov, ki so dosegli opazovane dogodke
If you have questions about how to inject, please ask your doctor or nurse for help. 
Če imate vprašanja o tem, kako injicirati, prosite za pomoč zdravnika ali medicinsko sestro.
In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or requiring hospitalisation or intravenous antibiotics) was observed. 
V preskušanjih, nadzorovanih s placebom, niso opazili zvečanja pojavnosti resnih okužb (s smrtnim izidom, življenjsko ogrožajočih okužb ali takih, ki so zahtevale hospitalizacijo ali intravenske antibiotike).
In a group of 7,416 patients treated with LIFMIOR in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis clinical trials, 18 lymphomas were reported. 
V skupini 7.416 bolnikov, zdravljenih z zdravilom LIFMIOR v kliničnih preskušanjih revmatoidnega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa in psoriaze, so poročali o 18 limfomih.
After removal of the needle cap, you will see a purple needle safety shield extending slightly from the end of the pen. 
Po odstranitvi pokrovčka igle boste videli vijolični varnostni ščit igle, ki sega nekoliko čez konec peresnika.
It is important that the vial adaptor spike completely penetrates the vial stopper. 
Pomembno je, da konica adapterja v celoti predre gumijasti zamašek viale.
If any serious allergic or anaphylactic reaction occurs, LIFMIOR therapy should be discontinued immediately and appropriate therapy initiated. 
Če se pojavi kakršnakoli resna alergijska ali anafilaktična reakcija, je treba zdravljenje s tem zdravilom takoj prekiniti in uvesti ustrezno zdravljenje.
In clinical trials, no interactions have been observed when LIFMIOR was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate. 
Med kliničnimi preskušanji niso opazili nobenih interakcij med zdravilom LIFMIOR in glukokortikoidi, salicilati (razen sulfasalazina), nesteroidnimi protivnetnimi zdravili (NSAIDs), analgetiki ali metotreksatom.
Concurrent treatment with sulfasalazine 
Sočasno zdravljenje s sulfasalazinom
After a single subcutaneous dose of 25 mg LIFMIOR, the average maximum serum concentration observed in healthy volunteers was 1.65 ± 0.66 μg/ml, and the area under the curve was 235 ± 96.6 μg•hr/ml. 
Po enkratnem subkutanem odmerku 25 mg zdravila LIFMIOR je bila povprečna največja koncentracija zdravila v serumu pri zdravih prostovoljcih 1,65  0,66 g/ml, površina pod krivuljo pa 235  96,6 g·h/ml.
Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on LIFMIOR continued to improve from month 3 through month 7, while those who received placebo did not improve. 
Od bolnikov, ki so dosegli klinični odziv do 90. dneva in se vključili v drugi del študije, se je pri nekaterih bolnikih, ki so ostali na zdravilu LIFMIOR, klinično stanje nadalje izboljševalo od 3. do 7. meseca zdravljenja, pri tistih, ki so v drugem delu študije prejemali placebo, pa izboljšanja ni bilo.
What LIFMIOR looks like and contents of the pack 
Izgled zdravila LIFMIOR in vsebina pakiranja
Subcutaneous use 
subkutana uporaba
Patients currently on methotrexate therapy (stable for ≥ 2 months) could continue at a stable dose of ≤ 25 mg/week methotrexate. 
Bolniki, ki so se takrat zdravili z metotreksatom (stabilno odmerjanje ≥ 2 meseca), so lahko nadaljevali s stalnim odmerkom metotreksata ≤ 25 mg/teden.
If the date has passed, do not use the pen and contact your pharmacist for assistance. 
Če je datum že potekel, peresnika ne uporabljate in se posvetujte s farmacevtom.
Caution should be exercised when considering TNF-antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy. 
Previdnost je potrebna pri razmisleku o uporabi antagonistov TNF pri bolnikih z anamnezo malignosti ali pri razmisleku o nadaljevanju zdravljenja pri bolnikih, pri katerih se pojavi malignost.
Compared to placebo, treatment with LIFMIOR resulted in significant improvements in the ASAS 20, ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy. 
V primerjavi s placebom je po dajanju zdravila LIFMIOR prišlo do izboljšanja pri ASAS 20, ASAS 50 in ASAS 70 že v 2 tednih od začetka zdravljenja.
• While holding the vial upright on the flat surface, push the plunger VERY SLOWLY until all the solvent is in the vial. 
Medtem ko držite vialo pokonci na ravni površini, potiskajte bat brizge ZELO POČASI, dokler ni ves vehikel v viali.
LIFMIOR is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. 
Zdravilo LIFMIOR je indicirano tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa pri odraslih, ki še niso dobivali metotreksata.
Patients treated with LIFMIOR should be given the Patient Alert Card. 
Bolniki, ki se zdravijo z zdravilom LIFMIOR, naj prejmejo opozorilno kartico za bolnika.
If re-treatment with LIFMIOR is indicated, the same guidance on treatment duration should be followed. 
Če je indicirano ponovno zdravljenje z zdravilom LIFMIOR, se moramo ravnati po istih smernicah glede trajanja zdravljenja.
LIFMIOR can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo LIFMIOR je mogoče uporabiti kot monoterapijo, kadar bolnik ne prenese metotreksata ali kadar trajno zdravljenje z metotreksatom ni primerno.
If the child has any of the above symptoms he/she may be having an allergic reaction to LIFMIOR, so you should seek immediate medical attention. 
Če ima otrok kateregakoli od zgoraj navedenih simptomov, ima mogoče alergijsko reakcijo na zdravilo LIFMIOR, zato morate nemudoma poiskati zdravniško pomoč.
However, it cannot be excluded that the combination of LIFMIOR with methotrexate could be associated with an increase in the rate of infections. 
Vendar pa ni mogoče izključiti možnosti, da se lahko stopnja pogostnosti okužb pri zdravljenju s kombinacijo zdravila LIFMIOR in metotreksata poveča.
TNF-antagonists, such as LIFMIOR, affect the immune system and their use may affect the body's defenses against infection and cancer. 
Antagonisti TNF, kot je zdravilo LIFMIOR, vplivajo na imunski sistem in lahko zmanjšajo sposobnost organizma za obrambo pred okužbami in rakom.
In another observational multi-country registry study comparing the risk of adverse pregnancy outcomes in women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for country, maternal disease, parity, maternal age and smoking in early pregnancy). 
V drugi opazovalni registrski študiji, ki so jo izvajali v več državah in v kateri so primerjali tveganje za neželene izide nosečnosti pri ženskah, izpostavljenih etanerceptu v prvih 90 dneh nosečnosti (n = 425), in pri ženskah, ki so bile izpostavljene nebiološkim zdravilom (n = 3.497), niso opazili povečanega tveganja za resne prirojene napake (grobo razmerje obetov [OR - Odds Ratio] = 1,22, 95 % IZ: 0,79-1,90; prilagojeno OR = 0,96, 95 % IZ: 0,58-1,60 po prilagoditvi glede na državo, materino bolezen, pariteto, starost matere in kajenje v zgodnji nosečnosti).
The most commonly reported invasive fungal infections included Candida, Pneumocystis, Aspergillus, and Histoplasma. 
Invazivne glivične okužbe, o katerih so najpogosteje poročali, so vključevale okužbe z vrstami Candida, Pneumocystis, Aspergillus in Histoplasma.
The safety and efficacy of LIFMIOR in patients with chronic infections have not been evaluated. 
Varnost in učinkovitost zdravila LIFMIOR pri bolnikih s kroničnimi okužbami nista bili ovrednoteni.
In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with LIFMIOR or placebo for moderate to severe alcoholic hepatitis, LIFMIOR was not efficacious, and the mortality rate in patients treated with LIFMIOR was significantly higher after 6 months. 
faze, v kateri so proučevali 48 hospitaliziranih bolnikov, zdravljenih z zdravilom LIFMIOR ali placebom zaradi zmernega do hudega alkoholnega hepatitisa, zdravilo LIFMIOR ni bilo učinkovito in stopnja smrtnosti bolnikov, zdravljenih z zdravilom LIFMIOR, je bila po 6 mesecih pomembno večja.
There have been rare reports of patients, including rheumatoid factor positive patients, who have developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy. 
O bolnikih, vključno z bolniki s pozitivnim revmatoidnim faktorjem, ki so razvili druga avtoprotitelesa v povezavi z lupusu podobnim sindromom ali izpuščaji, ki bi po klinični sliki in bioptičnem izvidu lahko pomenili subakutni kožni lupus ali diskoidni lupus, so poročali redko.
In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which LIFMIOR was added, patients in the combination group experienced a statistically significant decrease in mean white blood cell counts in comparison to groups treated with LIFMIOR or sulfasalazine alone. 
V klinični študiji odraslih bolnikov, ki so prejemali ustaljene odmerke sulfasalazina, ki mu je bilo dodano zdravilo LIFMIOR, se je pri bolnikih v skupini s kombinacijo obeh zdravil statistično pomembno zmanjšala povprečna koncentracija belih krvničk v primerjavi s skupinama, zdravljenima samo z zdravilom LIFMIOR ali samo s sulfasalazinom.
Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. 
Tumorje nekrotizirajoči faktor (TNF) je dominantni citokin v vnetnem procesu pri revmatoidnem artritisu.
Clearance is approximately 0.066 l/hr in patients with rheumatoid arthritis, somewhat lower than the value of 0.11 l/hr observed in healthy volunteers. 
Očistek pri bolnikih z revmatoidnim artritisom je približno 0,066 l/h, nekoliko nižji kot pri zdravih prostovoljcih, pri katerih znaša 0,11 l/h.
If you stop using LIFMIOR 
Če ste prenehali uporabljati zdravilo LIFMIOR
The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years were generally mild to moderate and consistent with those commonly seen in outpatient paediatric populations. 
Vrste okužb, ki so jih opazili v kliničnih preskušanjih pri bolnikih z juvenilnim idiopatskim artritisom, starih od 2 do 18 let, so bile na splošno blage do zmerne in skladne s tistimi, ki jih pogosto vidimo pri skupinah ambulantnih pediatričnih bolnikov.
The safety and efficacy of LIFMIOR in patients with immunosuppression have not been evaluated. 
Varnost in učinkovitost zdravila LIFMIOR pri bolnikih z imunosupresijo nista bili ovrednoteni.
Allergic reactions have included angioedema and urticaria; serious reactions have occurred. 
Alergijske reakcije so vključevale angioedem in urtikarijo, opisani pa so bili tudi primeri resnih reakcij.
Name and address of the manufacturers of the biological active substance Boehringer Ingelheim Pharma KG 
Ime in naslov izdelovalcev biološke učinkovine Boehringer Ingelheim Pharma KG Birkendorfer Strasse 65
The largest of these trials (n= 277) enrolled patients who were between 18 and 70 years of age and had active ankylosing spondylitis defined as visual analog scale (VAS) scores of ≥ 30 for average of duration and intensity of morning stiffness plus VAS scores of ≥ 30 for at least 2 of the following 3 parameters: patient global assessment; average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the Bath Ankylosing Spondylitis Functional Index (BASFI). 
Največje od teh preskušanj (n = 277) je vključevalo bolnike med 18. in 70. letom starosti z aktivnim ankilozirajočim spondilitisom, definiranim po vizualni analogni lestvici (VAS) z vrednostjo ≥ 30 za povprečno trajanje in intenzivnost jutranje okorelosti ter VAS vrednost ≥ 30 za vsaj 2 od 3 sledečih parametrov: bolnikova splošna ocena; povprečna VAS vrednost bolečine v hrbtenici ponoči in celokupne bolečine v hrbtenici; povprečje 10 vprašanj v Bath Ankylosing Spondylitis Functional Index (BASFI).
This will help to reduce foaming (lots of bubbles) (see Diagram 8). 
Tako boste zmanjšali penjenje raztopine (nastajanje mehurčkov) (glejte sliko 8).
After 12 weeks of treatment, 
Zdravljenje je trajalo 12 tednov.
• if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of LIFMIOR (listed in section 6). 
če ste vi ali otrok, za katerega skrbite, alergični na etanercept ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
Month 12 
12. mesec
• Not known (frequency cannot be estimated from the available data): Merkel cell carcinoma (a type of skin cancer); excessive activation of white blood cells associated with inflammation (macrophage activation syndrome); recurrence of hepatitis B (a liver infection); worsening of a condition called dermatomyositis (muscle inflammation and weakness with an accompanying skin rash). 
Neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): karcinom Merklovih celic (vrsta kožnega raka); čezmerna aktivacija belih krvničk, povezanih z vnetjem (sindrom aktivacije makrofagov); ponovitev hepatitisa B (vnetje jeter); poslabšanje stanja, imenovanega dermatomiozitis (vnetje mišic in mišična oslabelost, ki ju spremlja kožni izpuščaj).
Carcinogenicity studies, and standard assessments of fertility and postnatal toxicity, were not performed with LIFMIOR due to the development of neutralising antibodies in rodents. 
Študij kancerogenosti in standardnih raziskav plodnosti in postnatalne toksičnosti zaradi tvorbe nevtralizirajočih protiteles pri glodalcih niso opravili.
If you notice a spot of blood at the injection site, you should press the cotton ball or gauze over the injection site for 10 seconds. 
Če na mestu injiciranja opazite kapljo krvi, na mesto injiciranja za 10 sekund pritisnite vato ali gazo.
Compared to placebo, patients with rheumatic diseases treated with LIFMIOR had a significantly higher incidence of injection site reactions (36% vs. 9%). 
V primerjavi s placebom je bila pri bolnikih z revmatskimi obolenji, zdravljenih z zdravilom LIFMIOR, pojavnost reakcij na mestu injiciranja pomembno večja (36 % proti 9 %).
*see Description of selected adverse reactions, below. 
*glejte Opis izbranih neželenih učinkov v nadaljevanju
LIFMIOR showed statistically significantly greater improvement from baseline to week 12 compared to placebo in most health-related quality of life and physical function assessments, including BASFI (Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 Physical Component Score. 
Pokazali so, da je zdravilo LIFMIOR od izhodišča do 12 tednov statistično pomembno izboljšalo večino ocen z zdravjem povezane kakovosti življenja in telesne funkcije, vključno z BASFI (BASFIBath Ankylosing Spondylitis Functional Index; indeks Bath za ocenjevanje aktivnosti ankilizirajočega spondilitisa), rezultatom splošnega zdravstvenega stanja EuroQol 5D in rezultatom telesne komponente SF-36, v primerjavi s placebom.
Step 2: Choosing an injection site (see Diagram 2) 
Korak 2: Izbira mesta injiciranja (glejte sliko 2)
As you lift the pen, the purple needle safety shield will automatically extend to cover the needle. 
Ko peresnik umaknete, se bo vijolični varnostni ščit igle avtomatično podaljšal in pokril iglo.
Please tell your doctor if the child in your care has a history of alcohol abuse. 
Povejte zdravniku, če ima otrok, za katerega skrbite, zgodovino zlorabe alkohola.
The use of LIFMIOR is not expected to affect the ability to drive or use machines. 
Ni pričakovati, da bi zdravilo LIFMIOR vplivalo na sposobnost upravljanja vozil in strojev.